New York State Common Retirement Fund Cuts Stake in Abbott Laboratories $ABT

New York State Common Retirement Fund reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,032,443 shares of the healthcare product maker’s stock after selling 118,100 shares during the period. New York State Common Retirement Fund’s holdings in Abbott Laboratories were worth $272,225,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. IMG Wealth Management Inc. raised its position in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth about $32,000. Copia Wealth Management bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $38,000. Finally, Curio Wealth LLC boosted its holdings in Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after acquiring an additional 305 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $106.07 on Thursday. The firm has a 50-day moving average of $123.50 and a 200 day moving average of $127.80. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market cap of $184.44 billion, a P/E ratio of 28.51, a PEG ratio of 1.72 and a beta of 0.72. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s payout ratio is 67.74%.

Analysts Set New Price Targets

ABT has been the subject of several recent research reports. Royal Bank Of Canada lowered their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Barclays raised their price target on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Jefferies Financial Group boosted their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Finally, Benchmark initiated coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $140.75.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.